
Theranica’s Nerivio Reaches Coverage Milestone for Half of U.S. Insured
With 158 million covered lives now spanning the United States, Theranica’s Nerivio has reached a coverage threshold typically reserved for major pharmaceutical brands. The FDA-cleared wearable device, designed for acute and preventive migraine treatment, has doubled its reimbursement footprint over the last 15 months to capture half the insured population.



























